Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients
Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients
复制标题
DOI：
10.1097/01.tp.0000290678.06523.95
复制
发表时间：
2007-12-15
期刊：
影响因子：
6.2
通讯作者：
Tomlanovich, Stephen J.
中科院分区：
文献类型：
--
作者：
Bolin, Paul;Tanriover, Bekir;Tomlanovich, Stephen J.
背景。就胃肠道症状负担而言，从霉酚酸酯（MMF）转化为肠溶霉酚酸钠（EC-MPS）的益处先前已使用患者报告的结果进行了评估。然而，缺乏关于随时间转换的持续效果的数据，以及伴随的钙调磷酸酶抑制剂的潜在影响。在这项为期3个月、前瞻性、多中心、纵向、开放标签的试验中，mmf治疗的有胃肠道症状且接受环孢素或他克莫司治疗的肾移植患者被转换为等摩尔剂量的EC-MPS。采用经验证的胃肠症状评定量表（GSRS）评估胃肠道症状负担的变化。转化为EC-MPS后，GSRS评分从基线（2.61,95% CI 2.54-2.68）到第1个月（1.87,95% CI 1.81-1.93）显著改善，并持续到第3个月（1.81,95% CI 1.74-188）
Background. The benefit of conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) in terms of gastrointestinal symptom burden has been evaluated previously using patient- reported outcomes. However, data are lacking concerning the sustained effect of conversion over time, and the potential impact of concomitant calcineurin inhibitor.Methods. In this 3-month, prospective, multicenter, longitudinal, open-label trial, MMF-treated renal transplant patients with gastrointestinal symptoms receiving cyclosporine or tacrolimus were converted to equimolar doses of EC-MPS. Change in gastrointestinal symptom burden was evaluated using a validated Gastrointestinal Symptom Rating Scale (GSRS).Results. A significant improvement in GSRS score was observed from baseline (2.61, 95% CI 2.54-2.68) to month 1 (1.87, 95% CI 1.81-1.93) after conversion to EC-MPS and was sustained to month 3 (1.81, 95% CI 1.74-188; both P